What a new pancreatic cancer therapy signals for employer health costs

Scientific advances continue to expand treatment options for serious diseases. For employers and health plans, those advances also raise a practical question: how can you support access to effective care while managing a growing pipeline of high-cost therapies?

One recent example is the U.S. Food and Drug Administration (FDA) approval of daraxonrasib (Rasonque), a RAS inhibitor for certain adults with metastatic pancreatic adenocarcinoma. In the 500-patient RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with standard-of-care chemotherapy. These outcomes represent one of the most significant advances for one of the deadliest and most challenging cancers to treat in decades.

The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations and Priority Review. The drug was also selected for the FDA Commissioner’s National Priority Voucher pilot program. This is an initiative intended to accelerate review of therapies aligned with U.S. health priorities.

This clinical innovation comes with substantial cost. Revolution Medicines announced a wholesale acquisition cost of approximately $39,800 for a 30-day supply, translating to nearly $478,000 annually before rebates, discounts or patient assistance programs. The therapy offers meaningful survival benefits for patients with few remaining treatment options, but it also highlights a broader trend that is reshaping employer-sponsored healthcare.

High-cost therapies are reshaping employer spending

Groundbreaking therapies are now moving beyond traditional pharmaceuticals toward precision medicines, immunotherapies, cell therapies and gene therapies designed for specific biological targets. These treatments are improving outcomes in ways that weren’t previously possible, but many are entering the market with six- and seven-figure price tags.

Cancer continues to be one of the leading drivers of healthcare spend for employers, and oncology medications represent many of the highest-cost drugs in benefits plans. Innovation is accelerating, with novel targeted therapies, immunotherapies, personalized vaccines and biomarker-driven treatments expanding treatment options and improving outcomes, while increasing the financial complexity of managing cancer care.

These developments reinforce an important reality. Healthcare spending is increasingly being driven by pharmaceuticals rather than procedures. Our analyses show that drugs now account for approximately 40% of total healthcare costs for some employers, with specialty medications representing the fastest-growing component of spending.

Benefit strategy needs to account for oral targeted therapies

You’ll need to manage pharmaceuticals across both pharmacy and medical benefits. While many oncology and specialty drugs are infused, Rasonque is a daily pill. That means it will be processed through the pharmacy benefit manager. Oncology solutions and vendors must be prepared to address biomarker-driven targeted therapies sent through specialty pharmacies.

What you can do now

Therapies such as Rasonque demonstrate the life-changing value that new medicines can bring. You’ll need to balance access and affordability as more transformative therapies enter the market with prices measured in hundreds of thousands — or even millions — of dollars. As the pipeline expands, effective pharmacy strategy, forecasting, contracting and financial risk management will become as important as the clinical innovation itself.